These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27537604)

  • 1. The therapeutic potential of new investigational hepatitis C virus translation inhibitors.
    Borgia G; Maraolo AE; Buonomo AR; Scotto R; Gentile I
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1209-14. PubMed ID: 27537604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs in development for chronic hepatitis C: a promising future.
    Pockros PJ
    Expert Opin Biol Ther; 2011 Dec; 11(12):1611-22. PubMed ID: 21995412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entry inhibitors and future treatment of hepatitis C.
    Fofana I; Jilg N; Chung RT; Baumert TF
    Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of HCV antiviral drug resistance.
    Welsch C; Zeuzem S
    Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.
    Gentile I; Scotto R; Zappulo E; Buonomo AR; Pinchera B; Borgia G
    Expert Opin Investig Drugs; 2016; 25(5):557-72. PubMed ID: 26934419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Therapies for Hepatitis C Virus.
    Polenakovik H
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging treatments for hepatitis C.
    Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
    Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus resistance to the new direct-acting antivirals.
    Esposito I; Trinks J; Soriano V
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
    Fukasawa M
    Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prioritization of high-cost new drugs for HCV: making sustainability ethical.
    Craxì L; Sacchini D; Refolo P; Minacori R; Daloiso V; Ricci G; Bruno R; Cammà C; Cicchetti A; Gasbarrini A; Spagnolo AG
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1044-51. PubMed ID: 27049255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beclabuvir for the treatment of hepatitis C.
    Gentile I; Zappulo E; Buonomo AR; Maraolo AE; Borgia G
    Expert Opin Investig Drugs; 2015; 24(8):1111-21. PubMed ID: 26156630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational drugs for hepatitis C.
    Flisiak R; Parfieniuk A
    Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment failure with new hepatitis C drugs.
    Soriano V; Vispo E; Poveda E; Labarga P; Barreiro P
    Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of novel treatments for hepatitis C.
    Webster DP; Klenerman P; Collier J; Jeffery KJ
    Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in anti-viral therapeutics.
    Klebl BM
    Expert Opin Investig Drugs; 2005 Mar; 14(3):343-8. PubMed ID: 15833066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entry inhibitors: New advances in HCV treatment.
    Qian XJ; Zhu YZ; Zhao P; Qi ZT
    Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.